DXC Technology Unveils DXC Bionix™ to Provide Automated IT Services at Scale
DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, today unveiled DXC Bionix™, a new digital-generation services delivery model that promises to provide a comprehensive approach to intelligent automation at the scale required by the world’s top companies.
DXC Bionix leverages analytics and AI, lean processes and leading automation capabilities to produce greater insight, speed and efficiency across the company’s global delivery ecosystem. DXC is leveraging DXC Bionix to respond to client demand for greater IT performance and the need to digitally transform traditional IT environments and processes.
For DXC’s global delivery operations, the performance gains from DXC Bionix have been impressive:
- 50 percent to 80 percent reduction in time spent on operations;
- 25 percent reduction in testing costs; 50 percent defect reduction; 60 percent reduction in testing time;
- reduction in average applications deployment time from 180 minutes to 15 minutes;
- a 65 percent reduction in business process transaction time with assisted Robotic Process Automation (RPA);
- 71 percent of incidents auto-resolved or auto-diagnosed without human intervention; and
- an 82 percent elimination of issues through rules-based filtering and alert correlation.
“Technology innovation and intelligent automation are rapidly changing the IT services business, and clients want to maximize performance and business outcomes from technology investments,” said Stephen Hilton, executive vice president, Global Delivery, DXC Technology. “By bringing smart industrial engineering into our delivery processes, we can work in a highly dynamic, repeatable and scalable way to deliver exceptional and transformative solutions to our clients.”
DXC Bionix uses real-time data collection and analysis to continuously measure and elevate performance. This helps the company, and ultimately its clients, make more informed decisions, eliminate waste, and produce more predictable results.
“We are also empowering our workforce by investing in our people, driving a cultural shift and elevating skillsets to ensure that DXC has the right digital-generation talent to optimally meet current and future clients’ needs,” Hilton noted. “For DXC, our partners and clients, DXC Bionix enables us to work smarter, faster and more efficiently—achieving new thresholds of quality and performance.”
Combining Analytics and AI, Lean Processes, and Intelligent Automation
DXC Bionix provides a complete, high-definition view of the IT services delivery operating environment to yield deeper learning and more useful information. The result is fewer business disruptions, reduced human error and operational risks and lower costs. And because it enables Straight Through Processing, DXC Bionix becomes a smart, fast, performance-driven and secure delivery engine that increases performance and agility across the enterprise.
There are three core elements of DXC Bionix:
- Analytics and AI to gain new, real-time insights into the business and operations including data mining, machine learning and predictive intelligence to identify and proactively address opportunities for reducing costs and delivering innovation;
- Lean processes to eliminate inefficiencies and continually improve solutions delivery, and optimize work flows and team performance for better quality, consistency and outcomes; and
- Leading Automation capabilities, leveraging best-of-breed technologies from the DXC partner network combined with DXC innovation, to automate tasks, processes and workflows and to improve response time, accuracy and standardization.
“The next decade will see the mass adoption of artificial intelligence, machine learning and robotics within IT services which will reduce the unit cost of implementation,” Hilton added. “However, it will bring complexity.
“The competitive advantage of innovation will only be realized by companies that can simplify and manage this dynamic end-to-end at massive scale and as-a-service. DXC Bionix and its underlying platforms are how DXC will be at the forefront of this change, providing a competitive advantage for the company, our clients and partners.”
“A 70 percent reduction in backend incidents through predictive analytics is, from my stand point, amazing,” said Damian Bunyan, CIO, Uniper. “This is backed up by a near 20 percent automation of the remaining workload. This feeds directly into your business case (which is important) and provides welcome stability to my business units. I dream of such predictive maintenance in my generation fleet!”
Platform DXC and Agile Process Automation
Underpinning DXC Bionix is Platform DXC, the company’s digital-generation delivery platform that provides an important foundation for future services delivery — including applications, business process services, cloud, data analytics, security, and workplace and mobility solutions. Platform DXC allows DXC to quickly build and deliver partner-engineered, at-scale, repeatable offerings and solutions that help drive client digital transformations.
DXC’s recently announced Agile Process Automation (APA) is a new digital platform and a DXC Bionix enabled solution that combines cloud and robotic process automation (RPA) with embedded artificial intelligence (AI) to enhance a company’s business processes.
"Most end-user organizations don't have a line item in their budgets for digital transformation, so DXC Bionix is welcome news because it will help DXC identify where cash can be freed up from existing IT operations and reapplied to fund its clients' digital transformations," said Gard Little, vice president, Global Services Markets and Trends, IDC.
For more information on DXC Bionix, and to view a video featuring Steve Hilton, visit www.dxcbionix.com.
About DXC Technology
DXC Technology (NYSE: DXC) is the world’s leading independent, end-to-end IT services company, helping clients harness the power of innovation to thrive on change. Created by the merger of CSC and the Enterprise Services business of Hewlett Packard Enterprise, DXC Technology serves nearly 6,000 private and public sector clients across 70 countries. The company’s technology independence, global talent and extensive partner network combine to deliver powerful next-generation IT services and solutions. DXC Technology is recognized among the best corporate citizens globally. For more information, visit www.dxc.technology.
Richard Adamonis, Corporate Media Relations
Donna Jenks, Corporate Media Relations
Jonathan Ford, Investor Relations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i